VBLT Vascular Biogenics

VBL Therapeutics to Participate in the Guggenheim Oncology Conference and the 2022 BIO CEO & Investor Conference

VBL Therapeutics to Participate in the Guggenheim Oncology Conference and the 2022 BIO CEO & Investor Conference

TEL AVIV, Israel and NEW YORK, Feb. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will participate in a fireside chat at the Guggenheim Oncology Conference being held virtually on February 9 – 11, 2022. Management will also attend the BIO CEO & Investor Conference being held as a hybrid event on February 14 – 17, 2022.

Guggenheim Oncology Virtual Conference

Date: Thursday, February 10, 2022

Time: 10:00 a.m. ET

Format: Fireside Chat

Webcast:

2022 BIO CEO & Investor Conference

Date: February 14 – 17

Registration details for investor meetings and the event can be found .

A link to the webcast will also be available on the Events and Presentations page of the Investor Relations section on the Company’s website at .

About VBL Therapeutics

Vascular Biogenics Ltd., operating as VBL Therapeutics (VBL), is a late-clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for difficult-to-treat malignant solid tumors and immune or inflammatory indications. VBL’s novel VTS™ gene-based platform and antibody-based monocyte targeting technology enable the creation of a pipeline of programs that harness the body’s innate biological processes to provide unique solutions for significant unmet medical needs. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111; `ofra-vec`), is an investigational, first-in-class, targeted anti-cancer gene-based agent in development to treat a wide range of solid tumors. Ofra-vec is currently being studied in a Phase 3 registration-enabling clinical trial (NCT03398655) for platinum-resistant ovarian cancer. To learn more about VBL, please visit vblrx.com or follow the company on LinkedIn, Twitter, YouTube or Facebook.

CONTACT:

Daniel Ferry

LifeSci Advisors

+1 (617) 430-7576



EN
02/02/2022

Underlying

VBLTVascular Biogenics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vascular Biogenics

 PRESS RELEASE
Free
VBLT Vascular Biogen...

VBL Therapeutics Announces Results of Annual and Special Shareholder M...

VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI’IN, Israel and NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced that its shareholders voted to approve the previously announced proposed merger (the “Merger”) with Notable Labs, Inc. (“Notable”), at the annual and special meeting (...

October 12, 2023 1 EN
 PRESS RELEASE
Free
VBLT Vascular Biogen...

VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual a...

VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October 12, 2023 MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the “Merger”) with Notable Labs (“Notable”) at the annual and special meeting (the “Meeting”) for shareholders of record as of September 5, 2023. All VBL shareholders, regardless of...

October 4, 2023 1 EN
 PRESS RELEASE
Free
VBLT Vascular Biogen...

VBL Therapeutics Announces that S-4 Registration Statement for Propose...

VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced that its registration statement on Form S-4 in connection with the proposed merger with Notable Labs, Inc. (“Notable”) has been declared effective by the U.S. Securities and Exchange Commission (“SEC”...

September 6, 2023 1 EN
 PRESS RELEASE
Free
VBLT Vascular Biogen...

VBL Therapeutics Reports Second Quarter 2023 Financial Results and Pro...

VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective and shareholder approval $24.3 million in cash and cash equivalents as of June 30, 2023 MODI’IN, Israel and NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update. “We continue to make good progress towards the closing of o...

August 14, 2023 1 EN
 PRESS RELEASE
Free
VBLT Vascular Biogen...

VBL Therapeutics Reports First Quarter 2023 Financial Results and Prov...

VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update Recently filed S-4 registration statement for proposed merger with Notable; expects to close the transaction in Q3 2023, subject to SEC review and shareholder approvals MODI’IN, Israel and NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the first quarter ended March 31, 2023, and provided a corporate update. “During the first quarter, we made continued progress in the steps we are taking to maximize shareholder value and ar...

May 15, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch